“…This closed-loop technology, once further developed, would bypass the need for active monitoring or intervention by a human agent and raise ethical questions related to data privacy and security, patient informed consent and understanding ( Muñoz et al, 2020 ), and the need to preserve personal autonomy ( Zuk and Lázaro-Muñoz, 2019a ), agency, and identity ( Lázaro-Muñoz et al, 2017 ). When used in the context of experimental clinical settings, aDBS devices raise additional concerns about post-trial continued access ( Muñoz et al, 2020 ) to and/or removal of devices ( Sierra-Mercado et al, 2019 ) for participants in research trials after the study period is over. The intentional expansion of aDBS technology into the commercial sphere for non-clinical and elective ( Neuralink Inc, 2022 ) uses evokes further concerns, both practical (related to function and efficacy) and ethical (related to moral rightness or wrongness), revolving around safety (that it could potentially harm consumers) ( Jarchum, 2019 ), data security/privacy (brain activity could be accessed by unwanted third parties, “hacked” or otherwise exploited or exchanged as “currency” via licensing agreements) ( Dresler et al, 2018 ), and free will (that neuroenhancement may threaten our understanding of human agency, responsibility and liability) ( Nahmias et al, 2014 ; Klein et al, 2016 ).…”